MELBOURNE: Telix Pharmaceuticals Limited (ASX: TLX) has signed an agreement to acquire RLS (USA) Inc., from its parent company, RLS Group Ltd. The acquisition significantly expands Telix’s North American manufacturing footprint and establishes the basis of a next generation radiometal production network to benefit Telix and select strategic commercial partners. The acquisition of RLS is…
All posts tagged Telix Pharmaceuticals
Telix Pharmaceuticals launches IPO in United States
Melbourne: Telix Pharmaceuticals Limited (ASX: TLX) launched its initial public offering in the United States of AmericanDepositary Shares (ADSs), each representing one ordinary share in Telix. The target size of the offering is US$200 million in gross proceeds. In addition, Telix expects to grant the Underwriters (asdefined below) a 30-day option to purchase up to…
Telix Pharmaceuticals signs deal to acquire QSAM Biosciences for upto $123m
MELBOURNE, AUSTRALIA: Telix Pharmaceuticals Limited has entered into an agreement to acquire QSAM Biosciences, Inc. and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). The purchase price comprises US$33.1 million upfront, which is payable in the form of 4,369,914 Telix ordinary shares to be issued at closing, subject to certain cash adjustments (at or after closing) which…